Here are the top 5 biosimilar articles for the week of October 19, 2020.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of October 19, 2020.
Number 5: In an interview with The Center for Biosimilars®, Neuclone’s company strategic analyst, Thomas Wakim, said that the groundwork for its projected programmed death-1 (PD-1) inhibiting biosimilars for Keytruda (pembrolizumab) and Opdivo (nivolumab) are well underway.
Number 4:Alexion receives positive regulatory news in its bid to stay ahead of biosimilar competition, and Celltrion Group announces a phase 3 trial for its coronavirus disease 2019 (COVID-19) prophylactic drug candidate.
Number 3: Biosimilar competition for Roche added up to a $3.83 billion reduction in sales in the first 9 months of 2020, contributing to a sales decline of 4% in the United States for the pharmaceutical giant.
Number 2: Before its acquisition this year, Dean Foods attempted a specialty drug carve-out that led to a cost savings of $174,600 (77% reduction) by switching employees on a select number of originator specialty drugs to biosimilars.
Number 1: Amgen's 2020 biosimilar report goes into detail on how biosimilars have become more numerous in their first 5 years on the US market than biosimilars were in Europe in their first half decade.
To read all of these articles and more, visit centerforbiosimilars.com.